Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Forte Biosciences, Inc. - Common Stock
(NQ:
FBRX
)
76.99
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Aug 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Forte Biosciences, Inc. - Common Stock
< Previous
1
2
3
Next >
Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX
August 11, 2026
From
Kahn Swick & Foti, LLC
Via
Business Wire
FBRX Stock Alert: Halper Sadeh LLC is Investigating Whether Forte Biosciences, Inc. is Obtaining a Fair Price for its Shareholders
August 08, 2026
From
Halper Sadeh LLC
Via
Business Wire
Halper Sadeh LLC is Investigating Whether FBRX, LXFR, SMTI, MKTX are Obtaining Fair Deals for their Shareholders
August 05, 2026
From
Halper Sadeh LLC
Via
GlobeNewswire
Halper Sadeh LLC is Investigating Whether FBRX and SAFT are Obtaining Fair Deals for their Shareholders
July 28, 2026
From
Halper Sadeh LLC
Via
GlobeNewswire
Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX
July 28, 2026
From
Kahn Swick & Foti, LLC
Via
Business Wire
FBRX Stock Alert: Halper Sadeh LLC is Investigating Whether Forte Biosciences, Inc. is Obtaining a Fair Price for its Shareholders
July 27, 2026
From
Halper Sadeh LLC
Via
Business Wire
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline
July 27, 2026
From
Forte Biosciences, Inc.
Via
Business Wire
FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period
July 09, 2026
From
Forte Biosciences, Inc.
Via
Business Wire
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
May 11, 2026
From
Forte Biosciences, Inc.
Via
Business Wire
Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update
May 11, 2026
From
Forte Biosciences, Inc.
Via
Business Wire
Forte Biosciences Announces Pricing of $150 Million Public Offering
April 08, 2026
From
Forte Biosciences, Inc.
Via
Business Wire
Forte Biosciences Announces Proposed Public Offering
April 08, 2026
From
Forte Biosciences, Inc.
Via
Business Wire
Forte Biosciences, Inc. Announces 2025 Results and Provides Update
March 31, 2026
From
Forte Biosciences, Inc.
Via
Business Wire
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
March 17, 2026
From
Forte Biosciences, Inc.
Via
Business Wire
Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules
March 04, 2026
From
Forte Biosciences, Inc.
Via
Business Wire
Forte Biosciences, Inc. to Present at Upcoming Investor Meetings
February 09, 2026
From
Forte Biosciences, Inc.
Via
Business Wire
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
December 22, 2025
From
Forte Biosciences, Inc.
Via
Business Wire
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
November 24, 2025
From
Forte Biosciences, Inc.
Via
Business Wire
Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update
November 14, 2025
From
Forte Biosciences, Inc.
Via
Business Wire
Forte Biosciences, Inc. to Present at Upcoming Healthcare Conferences
November 03, 2025
From
Forte Biosciences, Inc.
Via
Business Wire
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
October 03, 2025
From
Forte Biosciences, Inc.
Via
Business Wire
Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium
September 15, 2025
From
Forte Biosciences, Inc.
Via
Business Wire
Forte Biosciences, Inc. Announces Results and Provides Update
August 14, 2025
From
Forte Biosciences, Inc.
Via
Business Wire
Forte Biosciences Announces Pricing of $75 Million Public Offering
June 25, 2025
From
Forte Biosciences, Inc.
Via
Business Wire
Forte Biosciences Announces Proposed Public Offering
June 24, 2025
From
Forte Biosciences, Inc.
Via
Business Wire
Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study
June 23, 2025
From
Forte Biosciences, Inc.
Via
Business Wire
Forte Biosciences, Inc. Announces Results and Provides Update
May 15, 2025
From
Forte Biosciences, Inc.
Via
Business Wire
Forte Biosciences, Inc. Announces Results and Provides Clinical Update
March 31, 2025
From
Forte Biosciences, Inc.
Via
Business Wire
Forte Biosciences, Inc. to Present at Upcoming Investor Meetings
February 03, 2025
From
Forte Biosciences, Inc.
Via
Business Wire
Forte Biosciences to Host R&D Day December 3, 2024
November 25, 2024
From
Forte Biosciences, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
